Madrigal Pharmaceuticals (MDGL) Income towards Parent Company (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Income towards Parent Company data on file, last reported at -$92.3 million in Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$92.3 million, down 26.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$304.1 million (up 22.35% YoY), and the FY2025 annual result was -$285.0 million, up 38.82% from the prior year.
• Income towards Parent Company slipped to -$92.3 million in Q1 2026 per MDGL's latest filing, from -$58.4 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$42.2 million in Q2 2025 and troughed at -$152.0 million in Q2 2024.
• A 5-year average of -$89.0 million and a median of -$85.8 million in 2023 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2024 and 2025: Income towards Parent Company sank 91.87% in 2024, then soared 72.21% in 2025.
• A 5-year view of Income towards Parent Company shows it stood at -$85.9 million in 2022, then plunged by 30.6% to -$112.2 million in 2023, then surged by 47.04% to -$59.4 million in 2024, then grew by 1.63% to -$58.4 million in 2025, then plunged by 57.89% to -$92.3 million in 2026.
• Business Quant data shows MDGL's Income towards Parent Company at -$92.3 million in Q1 2026, -$58.4 million in Q4 2025, and -$111.1 million in Q3 2025.